Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.
Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.
复制标题
DOI：
10.18632/oncotarget.7976
复制
发表时间：
2016-04-12
期刊：
影响因子：
--
通讯作者：
Tachezy M
中科院分区：
文献类型：
--
作者：
Gebauer F;Gelis S;Zander H;Meyer KF;Wolters-Eisfeld G;Izbicki JR;Bockhorn M;Tachezy M
生腱蛋白-C在大多数实体恶性肿瘤的间质中过表达，并且可以用作诊断肿瘤标志物。本研究旨在评估生腱蛋白-C作为非小细胞肺癌（NSCLC）患者血清中肿瘤进展的预测标志物的潜在意义。与健康对照相比，NSCLC患者中生腱蛋白-C的血清浓度显著升高（p=0.013）。Tenascin-C检测NSCLC的敏感性为74%，特异性为57%。升高的生肿蛋白-C血清值与较大的肿瘤尺寸和淋巴结受累相关（分别为p=0.022和p=0.036）。Kaplan-Meyer曲线显示腱生蛋白-C与患者的总生存期显著相关（p=0.004），但与无复发生存期无关（p=0.328）。我们定量Tenascin-C在103例NSCLC患者和76名健康献血员的血清中的酶联免疫吸附试验。通过曲线下面积分析和Youden指数确定预后意义。结果与临床、组织病理学和患者生存数据相关（卡方检验、Kaplan-Meier分析、对数秩检验、多变量Cox回归分析）。虽然在NSCLC患者中显著升高，但生腱蛋白-C血清定量测试的灵敏度和特异性较低。然而，尽管在多变量分析中未能成为独立的预测因子，但结果表明腱生蛋白-C是NSCLC患者的预测预后标志物。这些数据必须在未来更大患者队列的前瞻性试验中进一步验证。
Tenascin-C is overexpressed in the stroma of most solid malignancies and may function as a diagnostic tumor marker. This study was conducted to evaluate the potential significance of Tenascin-C as a predictive marker for tumor progression in the sera of non-small cell lung cancer (NSCLC) patients. Serum concentration of Tenascin-C is significantly elevated in NSCLC patients compared to healthy controls (p=0.013). The sensitivity of Tenascin-C in detecting NSCLC was 74% at a specificity of 57%. Elevated Tenascin-C serum values are associated with larger tumor size and lymph node involvement (p=0.022 and p=0.036, respectively). The Kaplan-Meyer-curves showed a significant association of Tenascin-C with the patient's overall survival (p=0.004), but not with the recurrence-free survival (p=0.328). We quantified Tenascin-C in the sera of 103 NSCLC patients and 76 healthy blood donors by enzyme-linked immune-absorbance assay tests. Prognostic significance was determined by area under the curve analysis and Youden-index. The results were correlated with clinical, histopathological, and patient survival data (Chi-square test, Kaplan-Meier analysis, log-rank test, multivariate Cox-regression analysis). Although significantly elevated in patients with NSCLC, the sensitivity and specificity of the Tenascin-C serum quantification test was low. However, although failing to be an independent prognosticator in multivariate analysis, the results implicate Tenascin-C as a predictive prognostic marker for NSCLC patients. The data must be further validated in future prospective trials with larger patient cohorts.